Dimensional Fund Advisors LP Cytom X Therapeutics, Inc. Transaction History

Dimensional Fund Advisors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$1.41 - $1.92 $170,033 - $231,534	-120,591 Reduced 77.08%	35,865 $61,000
Q1 2023 May 12, 2023	SELL	$1.48 - $2.88 $23,851 - $46,414	-16,116 Reduced 9.34%	156,456 $236,000
Q4 2022 Feb 09, 2023	SELL	$1.19 - $1.91 $9,529 - $15,295	-8,008 Reduced 4.43%	172,572 $276,000
Q3 2022 Nov 10, 2022	SELL	$1.23 - $1.97 $266,493 - $426,822	-216,661 Reduced 54.54%	180,580 $262,000
Q2 2022 Aug 12, 2022	SELL	$1.53 - $2.89 $630,205 - $1.19 Million	-411,899 Reduced 50.91%	397,241 $727,000
Q1 2022 May 13, 2022	BUY	$2.67 - $4.68 $766,591 - $1.34 Million	287,113 Added 55.0%	809,140 $2.16 Million
Q4 2021 Feb 09, 2022	BUY	$3.87 - $7.39 $770,122 - $1.47 Million	198,998 Added 61.6%	522,027 $2.26 Million
Q3 2021 Nov 12, 2021	SELL	$4.32 - $6.43 $1.35 Million - $2 Million	-311,364 Reduced 49.08%	323,029 $1.64 Million
Q2 2021 Aug 12, 2021	BUY	$6.33 - $9.91 $755,434 - $1.18 Million	119,342 Added 23.17%	634,393 $4.02 Million
Q1 2021 May 14, 2021	SELL	$6.6 - $9.0 $256,429 - $349,677	-38,853 Reduced 7.01%	515,051 $3.98 Million
Q4 2020 Feb 25, 2021	BUY	$6.47 - $7.9 $3.58 Million - $4.38 Million	553,904 New	553,904 $3.63 Million

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.